Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Stereotactic Radiosurgery (SRS)
Stereotactic Radiosurgery (SRS) for One or Two Localized Spine Metastases
Status: Enrolling
Updated:  9/23/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Stereotactic Radiosurgery (SRS)
Stereotactic Radiosurgery (SRS) for One or Two Localized Spine Metastases
Status: Enrolling
Updated: 9/23/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
Lovelace Sandia Health Systems Dept of Hematology
mi
from
Albuquerque, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
Lovelace Sandia Health Systems Dept of Hematology
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
University of New Mexico
mi
from
Albuquerque, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
St. Vincent Regional Medical Center
mi
from
Santa Fe, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
St. Vincent Regional Medical Center
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer
A Pilot Study of Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  9/27/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer
A Pilot Study of Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 9/27/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  10/4/2011
Georgetown University Medical Center
mi
from
Washington,
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 10/4/2011
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated:  10/5/2011
Highland Springs Medical Plaza
mi
from
Beaumont, CA
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated: 10/5/2011
Highland Springs Medical Plaza
mi
from
Beaumont, CA
Click here to add this to my saved trials
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated:  10/5/2011
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated: 10/5/2011
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Phase I Study of Single Dose Neoadjuvant Zoledronic Acid in Patients With Resectable Pancreas Cancer
Status: Enrolling
Updated:  10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Phase I Study of Single Dose Neoadjuvant Zoledronic Acid in Patients With Resectable Pancreas Cancer
Status: Enrolling
Updated: 10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status: Enrolling
Updated:  10/19/2011
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status: Enrolling
Updated: 10/19/2011
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Status: Enrolling
Updated:  10/25/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Status: Enrolling
Updated: 10/25/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib in Soft Tissue Sarcoma
A Phase II, Open-label, Non-randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Sunitinib in Soft Tissue Sarcoma
A Phase II, Open-label, Non-randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  10/28/2011
North Shore University Hospital
mi
from
Manhasset, NY
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 10/28/2011
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  10/28/2011
Columbia University Medical Center
mi
from
New York, NY
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 10/28/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
High Risk Prostate Cancer Prevention Study
High Risk Prostate Cancer Prevention Study
Status: Enrolling
Updated:  10/31/2011
University of Kansas Medical Center
mi
from
Kansas City, KA
High Risk Prostate Cancer Prevention Study
High Risk Prostate Cancer Prevention Study
Status: Enrolling
Updated: 10/31/2011
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
High Risk Prostate Cancer Prevention Study
High Risk Prostate Cancer Prevention Study
Status: Enrolling
Updated:  10/31/2011
Veterans Administration Medical Centenr
mi
from
Kansas City, MO
High Risk Prostate Cancer Prevention Study
High Risk Prostate Cancer Prevention Study
Status: Enrolling
Updated: 10/31/2011
Veterans Administration Medical Centenr
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated:  10/31/2011
University of Kansas Medical Center
mi
from
Kansas City, KA
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated: 10/31/2011
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Cabazitaxel - PF Induction Chemotherapy
Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/1/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Cabazitaxel - PF Induction Chemotherapy
Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/1/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/7/2011
Rush University Medical Center
mi
from
Chicago, IL
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/7/2011
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/7/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/7/2011
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Sharp Memorial Hospital
mi
from
San Diego, CA
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
University of Chicago Medical Center
mi
from
Chicago, IL
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
St. Agnes Hospital
mi
from
Baltimore, MD
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
St. Agnes Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Massachusetts General Hospital
mi
from
Boston, MA
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Park Nicollet Clinic - Cancer Center St. Louis Park
mi
from
St. Louis Park, MN
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Park Nicollet Clinic - Cancer Center St. Louis Park
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
South Texas Institute of Cancer
mi
from
Corpus Christi, TX
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
South Texas Institute of Cancer
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  11/7/2011
William Osler Health Center
mi
from
Brampton,
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 11/7/2011
William Osler Health Center
mi
from
Brampton,
Click here to add this to my saved trials
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma
Status: Archived
Updated:  11/17/2011
GSK Investigational Site
mi
from
Austin, TX
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma
Status: Archived
Updated: 11/17/2011
GSK Investigational Site
mi
from
Austin, TX
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
Status: Enrolling
Updated:  11/21/2011
University of Nevada School of Medicine
mi
from
Las Vegas, NV
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
Status: Enrolling
Updated: 11/21/2011
University of Nevada School of Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Moderating the Negative Impact of Abnormal Screening Mammograms
Moderating the Negative Impact of Abnormal Screening Mammograms
Status: Enrolling
Updated:  11/28/2011
University of WI Comprehensive Cancer Center and UW Health Clinics
mi
from
Madison, WI
Moderating the Negative Impact of Abnormal Screening Mammograms
Moderating the Negative Impact of Abnormal Screening Mammograms
Status: Enrolling
Updated: 11/28/2011
University of WI Comprehensive Cancer Center and UW Health Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Status: Enrolling
Updated:  12/1/2011
Division of Urology, Brown University
mi
from
Providence, RI
The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Status: Enrolling
Updated: 12/1/2011
Division of Urology, Brown University
mi
from
Providence, RI
Click here to add this to my saved trials
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  12/5/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 12/5/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated:  12/5/2011
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Status: Enrolling
Updated: 12/5/2011
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Status: Enrolling
Updated:  12/8/2011
Breastlink Med Group Inc
mi
from
Long Beach, CA
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Status: Enrolling
Updated: 12/8/2011
Breastlink Med Group Inc
mi
from
Long Beach, CA
Click here to add this to my saved trials
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Status: Enrolling
Updated:  12/8/2011
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Status: Enrolling
Updated: 12/8/2011
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Status: Enrolling
Updated:  12/8/2011
Advanced Medical Specialties
mi
from
Miami, FL
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Status: Enrolling
Updated: 12/8/2011
Advanced Medical Specialties
mi
from
Miami, FL
Click here to add this to my saved trials